WHY YOU'RE BEING DENIED
What Is Step Therapy?
The "Fail First" Rule
Step therapy requires you to try cheaper medications before your insurer will cover Wegovy. Even if your doctor prescribes Wegovy as the best option for you, insurers may deny it until you've "failed" other drugs first.[1]
When your insurer denies Wegovy due to step therapy, they're saying:
You must try lower-cost alternatives first
Insurers typically require you to try older, cheaper weight loss medications like orlistat, phentermine, or Contrave before approving Wegovy. This is primarily a cost-control measure—not necessarily based on what's most effective for you.[2]
You haven't documented "failure" on prior medications
"Failure" usually means:
- Less than 5% weight loss after 3+ months on the medication
- Intolerable side effects (documented by your provider)
- Medical contraindication (a condition that makes the medication unsafe for you)
If you've tried these medications but didn't document the results, your appeal will need to reconstruct that history.
The "required" medication trial wasn't long enough
Most insurers require 30-90 days (1-3 months) on each step therapy medication before considering it a "failure," though some plans require up to 6 months. If you stopped a medication after 4 weeks due to side effects, document exactly why—side effect discontinuation often qualifies as failure even with a shorter trial.[3]
The good news: Over 30 states have step therapy override laws that can help you skip these requirements. And with the right documentation, you can appeal successfully even without them.[4]
For a complete overview of all denial types, see our appeals guide.
Common Step Therapy Medications
These are the medications insurers typically require you to try before approving Wegovy:
| Medication | Trial Duration | Cost (no insurance) | Common Side Effects |
|---|---|---|---|
| Phentermine | 3 months | $15-50/mo | Increased heart rate, insomnia, dry mouth |
| Contrave (naltrexone/bupropion) | 3 months | $99-200/mo[12] | Nausea, constipation, headache |
| Qsymia (phentermine/topiramate) | 3 months | $98-250/mo[13] | Tingling, constipation, dry mouth |
| Orlistat (Xenical/Alli) | 3 months | $40-150/mo | Oily stools, gas, fecal urgency |
| Saxenda (liraglutide) | 3-6 months | $1,200-1,650/mo[14] | Nausea, diarrhea, constipation (GLP-1) |
Note: Costs shown are approximate retail prices. Manufacturer programs (like Contrave's $99/mo and Qsymia's $98/mo direct programs) can significantly reduce costs. Some insurers now require trying Zepbound or another GLP-1 before Wegovy.
Not Denied Yet? Understanding Requirements First
If you're still in the prior authorization process and want to understand what step therapy medications are required, see our prior authorization guide for a breakdown of common drugs, trial durations, and how to document properly.
Your GLP-1 coverage,
denied approved
Honest Care writes personalized, evidence-backed appeal letters — so you can fight back with confidence.
Need help appealing?
Get Started FreeWHAT YOUR DENIAL LETTER MEANS
Understanding Your Step Therapy Denial
Your denial letter should specify which medications you must try first (typically phentermine, Contrave, Qsymia, or Saxenda) and for how long. If it doesn't, call your insurer and request the exact step therapy criteria in writing.
Step Therapy Requirements by Insurer
Step therapy requirements vary significantly by insurer:
| Insurer | Step Therapy? | What's Required |
|---|---|---|
| Aetna | No medication step therapy | 6 months lifestyle modification only |
| UnitedHealthcare | Plan-dependent | Some plans require prior GLP-1 trial; check your specific plan |
| Cigna | Varies by plan | May require phentermine, Contrave, or other non-GLP-1 |
| BCBS | Varies by affiliate | Some require non-GLP-1 trial within 6 months[15] |
| CVS Caremark | Yes (many plans) | Zepbound often preferred; exception if intolerant |
| Express Scripts | Plan-dependent | Requirements vary; check formulary |
| Kaiser | Yes | Typically requires phentermine and/or Contrave first |
| Humana | Plan-dependent | Many plans require PA; step therapy varies |
Important: Policies change frequently. Always verify your specific plan's requirements by calling the number on your insurance card or checking your formulary. Illinois banned most step therapy as of January 2026 (HB 5395).[16]
Need Details on Full PA Requirements?
For complete prior authorization criteria by insurer (BMI thresholds, documentation needed, etc.), see our PA Requirements Guide.
Key question: Have you already tried any of these medications—even years ago or with a different insurer? If so, you may qualify for an exception without needing to try them again.
NEXT STEPS
How to Appeal a Step Therapy Denial
Step therapy denials can be appealed by documenting prior medication trials, contraindications, or adverse reactions. Most plans allow 180 days from your denial date to file, though timelines vary by insurer and state.[5]
For the complete step-by-step appeal process, see our Wegovy Appeals Guide.
VALID EXCEPTIONS
When You Can Skip Step Therapy
You may qualify for a step therapy exception if any of the following apply:
Prior Failure or Ineffectiveness
You've already tried the required medication(s) and:
- Failed to achieve 5% weight loss after adequate trial (typically 3+ months)
- Regained weight after initial success
- The medication was ineffective for your specific condition
Documentation needed: Pharmacy records, provider notes with dates/doses/outcomes
Medical Contraindication
The required medication cannot be safely used due to:
- Phentermine: Uncontrolled hypertension, cardiovascular (CV) disease, hyperthyroidism, glaucoma, pregnancy, history of drug abuse, MAOI (a type of antidepressant) use
- Orlistat: Chronic malabsorption syndrome, cholestasis (blocked bile flow)
- Contrave: Seizure disorders, eating disorders (anorexia/bulimia), concurrent opioid use, severe liver impairment
- Qsymia: Pregnancy or planning pregnancy, glaucoma, hyperthyroidism
Documentation needed: Medical records confirming the contraindicated condition
Adverse Reaction or Intolerance
You experienced significant side effects that prevented continued use:
- Severe GI (gastrointestinal/digestive) symptoms (orlistat)
- Cardiovascular effects—elevated heart rate or blood pressure (phentermine)
- Neurological symptoms—seizure, cognitive impairment (Qsymia)
- Psychiatric symptoms—depression, anxiety, suicidal ideation
Documentation needed: Provider notes documenting side effects and discontinuation reason
State Step Therapy Override Laws
Over 30 states have enacted step therapy override laws requiring insurers to grant exceptions when:[4]
- Required medication is contraindicated
- Patient has already failed or had adverse reaction to required medication
- Patient is stable on their current therapy
- Required medication is not in patient's best interest based on clinical evidence
Response timelines: Vary by state—check your state's insurance department for specific requirements[4]
Strong protection states: California, New York, Texas, Illinois, Michigan, Ohio[11]
Clinical Evidence Supports Wegovy Specifically
In some cases, clinical evidence may support bypassing step therapy:
- Wegovy's 14.9% weight loss (STEP 1 trial) significantly exceeds older medications (3-10%)[7]
- The SELECT trial demonstrated a 20% reduction in major cardiovascular events (heart attack, stroke, CV death)[8]
- Patient has comorbidities (other health conditions like cardiovascular disease or Type 2 diabetes) where greater weight loss and CV protection provide additional benefit
- Patient's BMI (body mass index) is significantly elevated, requiring more effective intervention
Documentation needed: Provider rationale explaining why Wegovy is uniquely appropriate
TEMPLATE FOR STEP THERAPY APPEALS
Sample Appeal Language
Customize for Your Situation
Use the language below as a starting point. Your appeal will be strongest when tailored to your specific history and circumstances.
Appeal Letter Framework
View Step Therapy Appeal Template
HEADER:
[Date] [Medical Director Name] [Insurance Company] [Address] Re: Step Therapy Exception Request for [Patient Name] Member ID: [Number] DOB: [Date] Case/Reference ID: [Number]
OPENING:
"Dear Medical Director, I am writing to request a step therapy exception for Wegovy (semaglutide) for [Patient Name]. The prior authorization was denied due to step therapy requirements. I respectfully request reconsideration based on the following clinical information demonstrating why step therapy should be waived."
EXCEPTION REASON (choose applicable):
If Prior Failure:
"[Patient Name] has previously tried [medication name] from [start date] to [end date] at [dose]. Despite adequate trial duration, the patient achieved only [X]% weight loss, below the clinically meaningful threshold of 5%. The medication was discontinued due to [inefficacy/side effects]. Documentation attached."
If Contraindication:
"[Patient Name] has a documented history of [condition], which is a contraindication to [required medication]. Specifically, [explain why the required medication cannot be safely used]. Per [guideline/prescribing information], [required medication] should not be used in patients with [condition]."
If Adverse Reaction:
"[Patient Name] previously tried [medication name] and experienced [specific adverse effects], which required discontinuation. These effects persisted despite dose adjustment and were intolerable for the patient. Given this documented intolerance, requiring a repeat trial would not be medically appropriate."
If State Law Applies:
"Pursuant to [State] step therapy override law [cite statute], [Patient Name] qualifies for a step therapy exception because [state specific qualifying reason]. This law requires the insurer to grant an exception within [72 hours/24 hours for urgent cases]."
CLINICAL JUSTIFICATION:
"Wegovy (semaglutide) is uniquely appropriate for [Patient Name] because: • BMI of [X] kg/m² with comorbidities including [list conditions] • The STEP 1 trial demonstrated 14.9% weight loss with Wegovy vs. 2.4% with placebo • The SELECT trial showed 20% reduction in major cardiovascular events (heart attack, stroke, CV death) • Patient has [established cardiovascular disease] where Wegovy's proven cardioprotective benefits are clinically indicated • Patient's [comorbidities/clinical situation] warrants more effective intervention"
CLOSING:
"Based on the above, requiring [Patient Name] to trial additional medications before Wegovy would delay necessary treatment for a serious chronic disease and is not supported by clinical evidence or applicable state law. Please contact me at [phone] with any questions. I request an expedited response due to the patient's clinical need. Sincerely, [Provider Name, Credentials] [NPI Number (provider ID)]"
Key Phrases for Step Therapy Appeals
| Situation | Effective Language |
|---|---|
| Prior medication failed | "Patient achieved only [X]% weight loss after [X] months of therapy, failing to meet the clinically meaningful threshold of 5%." |
| Side effects | "Patient experienced [specific effects] requiring discontinuation. A repeat trial would expose patient to known intolerable effects without reasonable expectation of benefit." |
| Contraindication | "Per FDA labeling, [medication] is contraindicated in patients with [condition]. Patient has documented [condition], making this medication medically inappropriate." |
| Clinical urgency | "Delay in effective treatment poses significant health risks given patient's BMI of [X] and comorbidities including [conditions]. Expedited review requested." |
| CV risk (Wegovy advantage) | "Given the patient's established cardiovascular disease, Wegovy's proven 20% reduction in MACE (SELECT trial) makes it the medically appropriate choice over alternatives without CV benefit." |
Official resource: Visit NovoCare's Wegovy savings page for additional appeal resources and savings programs.[9]
STEP THERAPY APPEALS
Frequently Asked Questions
Step therapy (also called "fail first") is an insurance policy that requires you to try cheaper, "preferred" medications before your insurer will cover Wegovy. Common step therapy medications include orlistat, phentermine, Contrave, and Qsymia. The idea is cost control—insurers want you to try less expensive options first, regardless of what your doctor recommends.
Trial duration varies by insurer—typically 30-90 days (1-3 months) per medication, though some plans require up to 6 months. If you experience intolerable side effects or have a medical contraindication, you may qualify for an exception without completing the full trial period. Document any adverse effects thoroughly with your provider and check your specific plan's requirements.
Possibly. If you've previously tried the required medications and they didn't work or caused side effects, you can request a step therapy exception based on "prior failure." However, documentation is key—you'll need pharmacy records and medical notes showing the medications you tried, dates, doses, and outcomes. Some insurers require trials within a recent look-back period (e.g., 6-12 months), so older trials may need additional justification from your doctor.
If you have a medical condition that makes the step therapy medication unsafe (a "contraindication"), you should qualify for an exception. For example, phentermine is contraindicated with uncontrolled hypertension, cardiovascular disease, or hyperthyroidism. Have your doctor document the contraindication in your appeal.
Approximately 34 states (about two-thirds) have step therapy override laws requiring insurers to grant exceptions under certain conditions—such as contraindication, prior failure, adverse reaction, or when the patient is stable on current therapy. Response timeframes vary by state. As of January 2026, Illinois, Connecticut, Maryland, and New York have enacted new protections. Check your state's insurance department website for specific rules.
Yes. Wegovy is the first weight-loss GLP-1 with an FDA-approved cardiovascular indication, for adults with established cardiovascular disease and either obesity or overweight (injection: March 8, 2024 (Wegovy injection); tablets: December 22, 2025 (Wegovy tablets)). The SELECT trial showed a 20% reduction in major cardiovascular events. While diabetes GLP-1s like Ozempic also have CV indications, Wegovy is the first obesity medication with this approval—an argument that older step therapy medications (which lack CV benefits) are not appropriate alternatives for patients with established cardiovascular disease.
YOUR PATH FORWARD
What's Next
Ready to Appeal?
65%+ of appeals succeed with proper documentation.[6] Our complete Wegovy appeals guide walks you through the entire process—from writing your appeal letter to requesting external review.
Other Common Denial Reasons
Denied for a different reason? See our guides for other denial types:
- Medical Necessity Not Met — Insurer says treatment isn't needed
- BMI Criteria Not Met — Weight thresholds not satisfied
- Formulary Exclusion — Drug not on plan's covered list
Not sure why you were denied? View all Wegovy denial types →
Your GLP-1 coverage,
denied approved
✓ Free Templates✓ Premium Support Available
I was denied coverage for...
Get startedWHAT'S CHANGING
Step Therapy: 2026 Outlook
2026: Step Therapy Requirements Expanding
More insurers are implementing step therapy for GLP-1 medications (a class of weight loss drugs), often requiring trials of metformin, phentermine, or older weight loss drugs before approving Wegovy.
State-Level Step Therapy Reform (January 2026)
Several states enacted new step therapy protections effective January 1, 2026:
- Illinois (HB 5395): Bans step therapy for most covered health plans (excludes self-insured employer plans and some Medicaid managed care)
- Maryland: Step therapy prohibited for Type 1, Type 2, and gestational diabetes medications, plus stage 4 metastatic cancer treatment
- Connecticut: Step therapy banned for multiple sclerosis, rheumatoid arthritis, major depressive disorder, bipolar disorder, and schizophrenia
- New York (A443): Extended step therapy protocol protections limiting insurer requirements
Check your state's insurance department website for specific protections that may apply to your situation.
Wegovy CV Indication: A Step Therapy Advantage
Wegovy's FDA-approved cardiovascular indication for adults with established cardiovascular disease and either obesity or overweight (injection: March 8, 2024 (Wegovy injection); tablets: December 22, 2025 (Wegovy tablets))[10] provides an argument against step therapy for patients in that population:
- The SELECT trial showed 20% reduction in major cardiovascular events[8]
- Older step therapy medications (phentermine, orlistat, Contrave) do NOT have proven cardiovascular benefits
- For patients with established cardiovascular disease, requiring inferior medications first may delay clinically necessary treatment
Use this argument in your appeal if you have established cardiovascular disease (such as a prior heart attack or stroke).
NovoCare Savings Programs
NovoCare offers savings programs that bypass insurance step therapy entirely:
- Wegovy savings card: Pay as little as $25 with eligible commercial insurance
- Cash-pay options available for patients without coverage
- Patient assistance programs for income-qualified patients
Visit NovoCare Wegovy Savings for current pricing and eligibility.
Denied Another GLP-1?
Step therapy requirements vary by medication. Explore appeal options:
References
- Wikipedia. "Step Therapy." https://en.wikipedia.org/wiki/Step_therapy
- GoodRx. (2025). "What is Step Therapy? How to Get Insurance to Pay for Your 'Non-Preferred' Drug." https://www.goodrx.com/drugs/savings/what-is-step-therapy
- Express Scripts. "Step Therapy Program Overview." https://www.express-scripts.com/art/pdf/SJM-STP.pdf
- Triage Cancer. (2025). "Health Insurance State Laws: Step Therapy." https://triagecancer.org/state-laws/health-insurance-step-therapy
- HealthCare.gov. "Internal Appeals." https://www.healthcare.gov/appeal-insurance-company-decision/internal-appeals/
- American Medical Association. (2024). "Over 80% of Prior Auth Appeals Succeed—Why Aren't There More?" 81% of MA appeals succeed; we use a conservative 65%+ estimate for commercial insurance. https://www.ama-assn.org/practice-management/prior-authorization/over-80-prior-auth-appeals-succeed-why-aren-t-there-more
- Wilding JPH, et al. (2021). "Once-Weekly Semaglutide in Adults with Overweight or Obesity." N Engl J Med. STEP 1 trial: 14.9% weight loss vs 2.4% placebo. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Lincoff AM, et al. (2023). "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes." N Engl J Med. SELECT trial: 20% reduction in MACE. https://pubmed.ncbi.nlm.nih.gov/37952131/
- Novo Nordisk. (2026). "NovoCare Wegovy Savings Offer." https://www.novocare.com/patient/medicines/wegovy/savings-offer.html
- U.S. Food & Drug Administration. (2024). "FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight." March 8, 2024. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or
- StepTherapy.com. (2024). "Step Therapy Legislation by State." Interactive map of state step therapy override laws. https://steptherapy.com/step-therapy-legislation-by-state/
- GoodRx. (2026). "Contrave Prices, Coupons & Savings Tips." Average retail ~$740/mo; manufacturer program $99/mo. goodrx.com/contrave
- GoodRx. (2026). "Qsymia Prices, Coupons & Savings Tips." Average retail ~$275/mo; manufacturer program $98/mo. goodrx.com/qsymia
- GoodRx. (2026). "How Much Is Saxenda Without Insurance?" Range $1,200-$1,650/mo at retail. goodrx.com
- SingleCare. (2025). "Wegovy Prior Authorization Criteria: Blue Cross Blue Shield." BCBS may require non-GLP-1 trial within 6 months. singlecare.com
- Illinois General Assembly. (2024). "HB 5395 - Step Therapy Reform." Bans step therapy for most covered health plans effective January 1, 2026. ilga.gov
Last updated October 6, 2026
Disclaimer
The information on this page is for educational and informational purposes only and is not intended as medical advice. Honest Care does not provide medical diagnosis, treatment, or individualized recommendations. Always seek the advice of your physician or other qualified healthcare professional regarding any medical condition or treatment.
While this content has been reviewed for accuracy and balance, new evidence may emerge after publication. Drug availability, indications, and insurance coverage can change over time. Honest Care makes no warranties as to completeness or currentness of the information and is not responsible for decisions made based on this content.